490 related articles for article (PubMed ID: 17637507)
1. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
Holder S; Lilly M; Brown ML
Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
[TBL] [Abstract][Full Text] [Related]
2. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
3. QSAR study of a large set of 3-pyridyl ethers as ligands of the alpha4beta2 nicotinic acetylcholine receptor.
Zhang H; Li H; Ma Q
J Mol Graph Model; 2007 Jul; 26(1):226-35. PubMed ID: 17208024
[TBL] [Abstract][Full Text] [Related]
4. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
5. Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel.
Brown ML; Zha CC; Van Dyke CC; Brown GB; Brouillette WJ
J Med Chem; 1999 May; 42(9):1537-45. PubMed ID: 10229624
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
Puntambekar D; Giridhar R; Yadav MR
Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.
Opera TI; Waller CL; Marshall GR
Drug Des Discov; 1994 Jul; 12(1):29-51. PubMed ID: 7578806
[TBL] [Abstract][Full Text] [Related]
8. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
[TBL] [Abstract][Full Text] [Related]
9. Comparison of estrogen receptor alpha and beta subtypes based on comparative molecular field analysis (CoMFA).
Xing L; Welsh WJ; Tong W; Perkins R; Sheehan DM
SAR QSAR Environ Res; 1999; 10(2-3):215-37. PubMed ID: 10491851
[TBL] [Abstract][Full Text] [Related]
10. Three-dimensional QSAR of HPPD inhibitors, PSA inhibitors, and anxiolytic agents: effect of tautomerism on the CoMFA models.
Zou JW; Luo CC; Zhang HX; Liu HC; Jiang YJ; Yu QS
J Mol Graph Model; 2007 Sep; 26(2):494-504. PubMed ID: 17418602
[TBL] [Abstract][Full Text] [Related]
11. Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.
Zhang QY; Wan J; Xu X; Yang GF; Ren YL; Liu JJ; Wang H; Guo Y
J Comb Chem; 2007; 9(1):131-8. PubMed ID: 17206841
[TBL] [Abstract][Full Text] [Related]
12. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
Pandey G; Saxena AK
J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
[TBL] [Abstract][Full Text] [Related]
13. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies.
Thaimattam R; Daga P; Rajjak SA; Banerjee R; Iqbal J
Bioorg Med Chem; 2004 Dec; 12(24):6415-25. PubMed ID: 15556759
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using CoMFA and CoMSIA methods.
Zhu YQ; Pei JF; Liu ZM; Lai LH; Cui JR; Li RT
Bioorg Med Chem; 2006 Mar; 14(5):1483-96. PubMed ID: 16256351
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR studies for the binding affinity toward (R, S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor.
Sharma RN; Thakar H; Vasu KK; Chaturvedi SC
Acta Pharm; 2008 Sep; 58(3):335-45. PubMed ID: 19103570
[TBL] [Abstract][Full Text] [Related]
17. 3D-QSAR analysis on benzazole derivatives as eukaryotic topoisomerase II inhibitors by using comparative molecular field analysis method.
Temiz-Arpaci O; Tekiner-Gulbas B; Yildiz I; Aki-Sener E; Yalcin I
Bioorg Med Chem; 2005 Dec; 13(23):6354-9. PubMed ID: 15993083
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
Yi P; Fang X; Qiu M
Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
[TBL] [Abstract][Full Text] [Related]
19. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
Ravindra GK; Achaiah G; Sastry GN
Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
[TBL] [Abstract][Full Text] [Related]
20. CoMFA based de novo design of pyridazine analogs as PTP1B inhibitors.
Nair PC; Sobhia ME
J Mol Graph Model; 2007 Jul; 26(1):117-23. PubMed ID: 17140831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]